Chemokines and dendritic cells in inflammatory myopathies

Annals of the Rheumatic Diseases

Volumn 68, Issue 3, 2009, Pages 300-304

  Tournadre, A ^a,b   Miossec, P ^a,c  

^a UNIVERSITÉ DE LYON   (France)

^b SERVICE DE RHUMATOLOGIE   (France)

^c EDOUARD HERRIOT HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; AUTOANTIGEN; CHEMOKINE; CYTOKINE; RITUXIMAB; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ADAPTIVE IMMUNITY; ANTIGEN PRESENTING CELL; CELL MATURATION; CYTOKINE PRODUCTION; DENDRITIC CELL; HUMAN; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; IMMUNOPATHOGENESIS; INFLAMMATORY CELL; INNATE IMMUNITY; LYMPHOCYTE DIFFERENTIATION; LYMPHOCYTE MIGRATION; MUSCLE CELL; MYOSITIS; PRIORITY JOURNAL; REVIEW; TH1 CELL; TH17 CELL;

CHEMOKINES; CYTOKINES; DENDRITIC CELLS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MUSCLE FIBERS, SKELETAL; MYOSITIS;

EID: 61449245620     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/ard.2008.095984     Document Type: Review

References (64)

1. Dalakas MC, Hohlfeld R. Polymyositis and dermatomyositis. Lancet 2003;362:971-82.
2. Bohan A, Peter JB. Polymyositis and dermatomyositis. N Engl J Med 1975;292:344-7.
3. Hengstman GJ, van Engelen BG. Polymyositis, invasion of non-necrotic muscle fibres, and the art of repetition. BMJ 2004;329:1464-7.
4. Page G, Chevrel G, Miossec P. Anatomic localization of immature and mature dendritic cell subsets in dermatomyositis and polymyositis: interaction with chemokines and TM cytokine-producing cells. Arthritis Rheum 2004;50:199-208.
5. Emslie-Smith AM, Arahata K, Engel AG. Major histocompatibility complex class I antigen expression, immunolocalization of interferon subtypes, and T cell-mediated cytotoxicity in myopathies. Hum Pathol 1989;20:224-31.
6. Hoogendijk JE, Amato AA, Lecky BR, Choy EH, Lundberg IE, Rose MR, et al. 119th ENMC international workshop: Trial design in adult Idiopathic inflammatory myopathies, with the exception of inclusion body myositis. Neuromuscul Disord 2004;14:337-45.
7. Lundberg I, Ulfgren A.K. Nyberg P, Andersson U, Klreskog L. Cytokine production in muscle tissue of patients with idiopathic inflammatory myopathies. Arthritis Rheum 1997;40:865-74.
8. Bell D, Young J.W, Banchereau J. Dendritic cells. Adv Immunol 1999;72:255-324.
9. Steinman RM, Hawiger D, Nussenzweig MC. Tolerogenic dendritic cells. Annu Rev Immunol 2003;21:685-711.
10. Greenberg SA, Pinkus JL, Pinkus GS, Burleson T, Sanoudou D, Tawil R, et al. Interferon-alpha/beta-mediated innate immune mechanisms in dermatomyosltis. Ann Neurol 2005;57:664-78.
11. López de Padilla CM, Vallejo AN, McNallan KT, Vehe R, Smith SA, Dietz AB, et al. Plasmacytoid dendritic cells in inflamed muscle of patients with juvenile dermatomyositis. Arthritis Rheum 2007;56:1658-68.
12. Greenberg SA, Pinkus GS, Amato AA, Pinkus JL Myeloid dendritic cells in inclusion-body myositis and polymyositis. Muscle Nerve 2007;35:17-23.
13. Eloranta ML, Barbasso Helmers S, Ulfgren AK, Rönnblom L, Aim GV, Lundberg IE. A possible mechanism for endogenous activation of the type I interferon system in myositis patients with anti-Jo-1 or anti-Ro 52/anti-Ro 60 autoantibodies. Arthritis Rheum 2007;56:3112-24.
14. Walsh RJ, Kong SW, Yao Y, Jallal B, Kiener PA, Pinkus JL, et al. Type I interferon-inducible gene expression in blood is present and reflects disease activity in dermatomyosltis and polymyositis. Arthritis Rheum 2007;56:3784-92.
15. Halloran PF, Urmson J, Van der Meide PH, Autenried P. Regulation of MHC expression in vivo. II. IFN-alpha/beta inducers and recombinant IFN-alpha modulate MHC antigen expression in mouse tissues. J Immunol 1989;142:4241-7.
16. Nagaraju K, Raben N, Loeffler L, Parker T, Rochon PJ, Lee E, et al. Conditional up-regulation of MHC class I in skeletal muscle leads to self-sustaining autoimmune myositis and myosltis-specific autoantibodies. Proc Natl Acad Sci USA 2000;97:9209-14.
17. Olson TS, Ley K. Chemokines and chemokine receptors in leukocyte trafficking. Am J Physiol Regul Integr Comp Physiol 2002;283:R7- 28.
18. Civatte M, Bartoli C, Schleinitz N, Chetaille B, Pellissier JF, Figarella-Branger D. Expression of the beta chemokines CCL3, CCL4, CCL5 and their receptors in idiopathic inflammatory myopathies. Neuropathol Appl Neurobiol 2005;31:70-9.
19. Dieu MC, Vanbervliet B, Vicarl A, Bridón JM, Oldham E, Ait-Yahla S, et al. Selective recruitment of immature and mature dendritic cells by distinct chemoklnes expressed in different anatomic sites. J Exp Med 1998;188:373-86.
20. Page G, Lebecque S, Miossec P. Anatomic localization of immature and mature dendritic cells in an ectopic lymphoid organ: correlation with selective chemokine expression in rheumatoid synovium. J Immunol 2002;168:5333-41.
21. Ngo VN, Tang HL, Cyster JG. Epstein-Barr virus-induced molecule 1 ligand chemokine is expressed by dendritic cells in lymphoid tissues and strongly attracts naive T cells and activated B cells. J Exp Med 1998;188:181-91.
22. Minetti C, Gattorno M, Repetto S, Gregorio A, Pedemonte M, Assereto S, et al. Chemokine receptor CCR7 is expressed in muscle fibers in juvenile dermatomyositis. Biochem Biophys Res Commun 2005;333:540-3.
23. Tateyama M, Fujihara K, Misu T, Feng J, Onodera Y, Itoyama Y. Expression of CCR7 and its ligands CCL19/CCL21 in muscles of polymyositis. J Neurol Sci 2006 15;249:158-65.
24. Lepidi H, Frances V, Figarella-Branger D, Bartoli C, Machado-Baeta A, Pellissler JF. Local expression of cytokines in idiopathic inflammatory myopathies. Neuropathol Appl Neurobiol 1998;24:73-9.
25. Tews DS, Goebel HH. Cytokine expression profile in idiopathic inflammatory myopathies. J Neuropathol Exp Neurol 1996;55:342-7.
26. De Bleecker JL, Meire VI, Declercq W, Van Aken EH. Immunolocalizatlon of tumor necrosis factor-alpha and its receptors in inflammatory myopathies. Neuromuscul Disord 1999;9:239-46.
27. Grundtman C, Salomonsson S, Dorph C, Bruton J, Andersson U, Lundberg IE. Immunolocalization of interleukin-1 receptors in the sarcolemma and nuclei of skeletal muscle in patients with idiopathic inflammatory myopathies. Arthritis Rheum 2007;56:674-87.
28. De Bleecker JL, Engel AG. Expression of cell adhesion molecules in inflammatory myopathies and Duchenne dystrophy. J Neuropathol Exp Neurol 1994;53:369-76.
29. Lundberg I, Brengman JM, Engel AG. Analysis of cytokine expression in muscle in inflammatory myopathies, Duchenne dystrophy, and non-weak controls. J Neuroimmunol 1995;63:9-16.
30. Tucci M, Quatraro C., Dammacco F, Silvestris F. Interleukin-18 overexpression as a hallmark of the activity of autoimmune inflammatory myopathies. Clin Exp Immunol 2006;146:21-31.
31. Kaser A, Kaser S, Kaneider NC, Enrich B, Wiedermann CJ, Tilg H. Interleukin-18 attracts plasmacytoid dendritic cells (DC2s) and promotes Th1 induction by DC2s through IL-18 receptor expression. Blood 2004;103:648-55.
32. Harrington LE, Hatton RD, Mangan PR, Turner H, Murphy TL, Murphy KM, et al. Interleukin 17-produclng CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat Immunol 2005;6:1123-32.
33. Park H, LI Z, Yang XO, Chang SH, Nurieva R, Wang YH, et al. A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17. Nat Immunol 2005;6:1133-41.
34. Chabaud M, Fossiez F, Taupin JL, Miossec P. Enhancing effect of IL-17 on IL-1-induced IL-B and leukemia Inhibitory factor production by rheumatoid arthritis synoviocytes and its regulation by Th2 cytokines. J Immunol 1998;161:409-14.
35. Chevrel G, Page G, Granet C, Streichenberger N, Varennes A, Miossec P. Interleukin-17 increases the effects of IL-1 beta on muscle cells: arguments for the role of T cells in the pathogenesis of myositis. J Neuroimmunol 2003;137:125-33.
36. De Rossi M, Bernasconi P, Baggi F, de Waal Malefyt R, Mantegazza R. Cytokines and chemokines are both expressed by human myoblasts: possible relevance for the Immune pathogenesis of muscle inflammation, Int Immunol 2000;12:1329-35.
37. Bartocionni E, Gallucci S, Scuderi F, Ricci E, Servidei S, Broccolini A, et al. MHC class I, MHC class Il and intercellular adhesion molecule-1 expression in inflammatory myopathies. Clin Exp Immunol 1994;95:166-72.
38. Gallucci S, Provenzano C, Mazzarelll P, Scuderi F, Bartoccioni E. Myoblasts produce IL-B in response to inflammatory stimuli, Int Immunol 1998;10:267-73.
39. Nagaraju K, Raben N, Merritt G, Loeffler L, Kirk K, Plotz P. A variety of cytokines and Immunologically relevant surface molecules are expressed by normal human skeletal muscle cells under proinflammatory stimuli. Clin Exp Immunol 1998;113:407-14.
40. Jo C, KIm H, Jo I, Choi I, Jung SC, Kim J, et al. Leukemia inhibitory factor blocks early differentiation of skeletal muscle cells by activating ERK. Biochim Biophys Acta 2005;1743:187-97.
41. Ebisui C, Tsujinaka T, Morimoto T, Kan K, Iijima S, Yano M, et al. lnterleukin-6 Induces proteolysis by activating Intracellular proteases (cathepslns B and L, proteasome) in C2C12 myotubes. Clin Sci (Lond) 1995;89:431-9.
42. Austin L, Burgess AW. Stimulation of myoblast proliferation in culture by leukaemia Inhibitory factor and other cytokines. J Neurol Sci 1991;101:193-7.
43. Casciola-Rosen L, Nagaraju K, Plotz P, Wang K, Levine S, Gabrielson E, et al. Enhanced autoantigen expression in regenerating muscle cells in idiopathic Inflammatory myopathy.J Exp Med 2005;201:591-601.
44. Howard OM, Dong HF, Yang D, Raben N, Nagaraju K, Rosen A, et al. Histidyl-tRNA synthetase and asparaginyl-tRNA synthetase, autoantigens in myositis, activate chemokine receptors on T lymphocytes and Immature dendritic cells. J Exp Med 2002;196:781-91.
45. Levine SM, Rosen A, Casciola-Rosen LA. Anti-aminoacyl tRNA synthetase Immune responses: insights into the pathogenesis of the idiopathic Inflammatory myopathies. Curr Opin Rheumatol 2003;15:708-13.
46. Suber TL, Casciola-Rosen L, Rosen A. Mechanisms of disease: autoantigens as clues to the pathogenesis of myositis. Nat Clin Pract Rheumatol 2008;4:201-9.
47. Goebels N, Michaelis D, Wekerle H, Hohlfeld R. Human myoblasts as antigen-presenting cells. J Immunol 1992;49:661-7.
48. Michaelis D, Goebels N, Hohlfeld R. Constitutive and cytokine-induced expression of human leukocyte antigens and cell adhesion molecules by human myotubes. Am J Pathol 1993;143:1142-9.
49. Marino M, Scuderl F, Mazzarelli P, Mannella F, Provenzano C, Bartoccioni E. Constituve and cytokine-induced expression of MHC and intercellular adhesion molecule-1 on human myoblasts. J Neuroimmunol 2001;116:94-101.
50. Lundberg I, Kratz A.K. Alexanderson H, Patarroyo M. Decreased expression of interleuklne-1α, interleukine-1β, and cell adhesion molecules in muscle tissue following corticosteroid treatment in patients with polymyositis and dermatomyosltis. Arthritis Rheum 2000;43:336-48.
51. Bernasconi P, Confalonieri P, Andreetta F, Baggi F, Cornelio F, Mantegazza R. The expression of co-stimulatory and accessory molecules on cultured human muscle cells is not dependent on stimulus by proinflammatory cytokines: relevance for the pathogenesis of Inflammatory myopathy. J Neuroimmunol 1998;85:52-8.
52. Nagaraju K, Raben N, Villalba ML. Costimulatory markers in muscle of patients with idiopathic inflammatory myopathies and in cultured muscle cells. Clin Immunol 1999;92:161-9.
53. Murata K, Dalakas MC. Expression of the costimulatory molecule BB-1, the ligands CTLA-4 and CD28, and their mRNA in inflammatory myopathies. Am J Pathol 1999;155:453-60.
54. Wiendl H, Mitsdoerffer M, Schneider D, Chen L, Lochmüller H, Melms A, et al. Human muscle cells express a B7-related molecule, B7-H1, with strong negative immune regulatory potential: a novel mechanism of counterbalancing the immune attack in Idiopathic inflammatory myopathies. FASEB J 2003;17:1892-4.
55. Chevrel G, Granet C, Miossec P. Contribution of tumour necrosis factor alpha and interleukin (IL) 1beta to IL6 production, NF-kappaB nuclear translocation, and class I MHC expression in muscle cells: in vitro regulation with specific cytokine inhibitors, Ann Rheum Dis 2005;64:1257-62.
56. Iannone F, Scioscla C, Falappone PC, Covelli M, Lapadula G. Use of etanercept in the treatment of dermatomyosltis: a case series. J Rheumatol 2006;33:1802-4.
57. Efthimiou P, Schwartzman S, Kagen LJ. Possible role for tumour necrosis factor inhibitors in the treatment of resistant dermatomyosltis and polymyositis: a retrospective study of eight patients. Ann Rheum Dis 2006;65:1233-6.
58. Hengstman GJ, De Bleecker JL, Feist E, Vlssing J, Denton CP, Manoussakls MN, et al. Open-label trial of anti-TNF-alpha in dermato- and polymyositis treated concomitantly with methotrexate. Eur Neurol 2008;59:159-63.
59. Dastmalchi M, Grundtman C, Alexanderson H, Mavragani CP, Elnarsdottir H, Barbasso Helmers S, et al. A high incidence of disease flares in an open pilot study of infliximab in patients with refractory inflammatory myopathies. Ann Rheum Dis 2008;67:1670-7.
60. Chabaud M, Page G, Miossec P. Enhancing effect of IL-I, IL-17. and TNF-alpha on macrophage inflammatory protein-3alpha production in rheumatoid arthritis: regulation by soluble receptors and Th2 cytokines. J Immunol 2001;167:6015-20.
61. Levine TD. Rituximab in the treatment of dermatomyositis: an open-label pilot study. Arthritis Rheum 2005;52:601-7.
62. Mok CC, Ho LY, To CH. Rituximab for refractory polymyositis: an open-label prospective study.J Rheumatol 2007;34:1864-8.
63. Kremer JM, Dougados M, Emery P, Durez P, Sibillia J, Shergy W, et al. reatment of rheumatoid arthritis with the selective costimulation modulator abatacept: twelvemonth results of a phase iib, double-blind, randomized, placebo-controlled trial. Arthritis Rheum 2005;52:2263-71.
64. Nagaraju K, Casciola-Rosen L, Lundberg I, Rawat R, Cutting S, Thapliyal R, et al. Activation of the endoplasmic reticulum stress response in autoimmune myositis: potential role in muscle fiber damage and dysfunction. Arthritis Rheum 2005;52:1824-35.